Navigation Links
Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic,Colorectal Cancer Patients Published

-expressing, metastatic colorectal cancer is based on progression-free survival. Currently no data are available that demonstrate increased survival with Vectibix.

As seen in previous analyses of these data, the Vectibix group showed a statistically significant improvement in progression-free survival versus those who received BSC alone yielding a 46 percent decrease in the relative progression rate. The mean progression-free survival was 96 versus 60 days.

A blinded central review showed that 10 percent of patients in the Vectibix group had an objective response, while no patients in the BSC group demonstrated an objective response. Median time to response was 7.9 weeks and median duration of response was 17 weeks.

In the BSC group 174 (75 percent) patients received Vectibix under the crossover protocol. In those patients that crossed over, the objective response rate was 10 percent. The median time to crossover was 7.0 (6.6, 7.3) weeks. The median follow-up after crossover was 27 (4-69) weeks.

In the primary analysis of overall survival, there was no significant difference between the groups. The median follow-up time was 72 weeks for all patients.

A broadly-based clinical development program designed to examine the utility of Vectibix in the first- and second-line treatment of metastatic colorectal cancer, as well as head and neck cancer is ongoing.

Important Product Safety Information

As described below, the Vectibix Prescribing Information includes warning language:

Dermatologic toxicities, related to Vectibix blockade of EGF binding and subsequent inhibition of EGFr-mediated signaling pathways, were reported in 89 percent of patients and were severe (NCI-CTC grade 3 and higher) in 12 percent of patients receiving Vectibix monotherapy. The clinical manifestations included, but were not limited to, dermatitis acneiform, pruritus, erythema, rash, skin exfoliation, paronychia, dry skin, and skin fissures. Sev
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
2. Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
3. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
4. Intarcia Therapeutics Announces Final Results From a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1
5. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
6. Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:7/30/2015)... 30, 2015  Today we bring you a special edition of #MedicareMonday on Medicare,s ... about some of our Medicare resources and continue highlighting the success of the prescription ... Check out our latest infographics and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
(Date:7/30/2015)... CHENGDU, China , July 30, 2015 ... "Company"), a pharmaceutical company that specializes in the patented ... active pharmaceutical ingredients (API), provided updates regarding the notice ... MKT LLC (the "Exchange") indicating that the Company was ... set forth in Sections 134 and 1101 of the ...
Breaking Medicine Technology:Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... the "NEXT" Study Also Showed Arzoxifene Significantly Suppressed ... with OsteoporosisATHENS, Greece, March 23 Eli Lilly ... new data showing arzoxifene, an investigational selective estrogen ... increasing bone mineral density (BMD) in the lumbar ...
... Santaris Pharma announced today that,the fourth LNA-based drug ... USA,several patients with cancer have now been treated ... by Santaris Pharma and Enzon,Pharmaceuticals. The U.S. Food ... New Drug (IND) application,for the use of the ...
Cached Medicine Technology:Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 2Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 3Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 4Phase III Trial Showed Investigational Compound Arzoxifene Was Superior to Evista(R) (raloxifene HCl) in Increasing BMD in Postmenopausal Women with Osteoporosis 5Another LNA-based RNA Inhibitor Enters Clinical Trials 2Another LNA-based RNA Inhibitor Enters Clinical Trials 3
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical ... PRO this week. Zeltiq Aesthetics released this new applicator in the United States ... for treating the outer thighs. The original applicator required a 2 hour treatment ...
(Date:7/31/2015)... ... ... Coco Libre announced today that their flagship Organic Coconut Water will be ... Open of Surfing, July 25 through August 2 in Huntington Beach, California. Coco Libre, ... is a natural choice given the Open’s commitment to sustainable practices. , Designated ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article published July ... they could reach a consensus on the steps that need to be taken to ... reached 90 percent consensus on a series of steps that each surgeon must complete ...
(Date:7/31/2015)... ... 31, 2015 , ... As part of their company mission, Dallas pet ... welfare organizations is essential to the longevity of their business. It is for ... of Professional Pet Sitters (NAPPS) annual Presents 4 Pets supply drive. Presents ...
(Date:7/31/2015)... ... July 31, 2015 , ... “Engage: Don’t Just ... industry’s premier thought leadership symposiums, hosted by Massachusetts-based Harmony Healthcare International at ... attracts over 250 “C”-level executives, administrators, directors of nursing, rehabilitation managers and other ...
Breaking Medicine News(10 mins):Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3
... Your Baby a Healthy Start in Life, NEW ... a,whole new outlook on being eco-friendly. But choosing the ... young children can,be a source of anxiety for many ... Dimes luncheon for reporters here,titled "The Eco-Friendly Baby: Common ...
... announces the,compatibility of its revolutionary Onyx(R) II, Model ... health platform, Microsoft,HealthVault. The Onyx II 9560 is ... device to wirelessly transfer monitored SpO2 and pulse,rate ... manage,store, share and review their health information with ...
... from IAC/InterActive Corp, Leading, Health Network Moves ... ARLINGTON, Va., June 10 The HealthCentral Network, ... consumer health,information company MedTrackAlert, LLC. The move more ... and offers advertisers more ways,to reach high-quality audiences ...
... science academies for the G8+5 countries issued statements urging ... challenges. To mitigate and adapt to climate change, ... a shift that will require energy-saving changes in all ... and the development of a range of clean energy ...
... ... beginning, and I thought, ,What the h--- have I ... done?, - Marcia Cross, Morning sickness can strike at any time and ... first,nutrition bar with DHA and engineered to meet the special dietary needs of,women who are ...
... 10 Blue Cross and Blue Shield,of Florida, ... Health Plans in Florida," for the second year ... Associates 2008 National Health Insurance,Plan Study(SM)., (Logo: ... ), BCBSF received the highest numerical ...
Cached Medicine News:Health News:The Eco-friendly Mom and Baby for the 21st Century 2Health News:The Eco-friendly Mom and Baby for the 21st Century 3Health News:Nonin(R) Medical Announces Strategic Relationship With Microsoft and its Microsoft HealthVault Platform 2Health News:The HealthCentral Network Acquires MedTrackAlert, Extending its Ability to Reach Highly Engaged Online Health Consumers 2Health News:The HealthCentral Network Acquires MedTrackAlert, Extending its Ability to Reach Highly Engaged Online Health Consumers 3Health News:The HealthCentral Network Acquires MedTrackAlert, Extending its Ability to Reach Highly Engaged Online Health Consumers 4Health News:Oh Mama! Heads Back to the Lab to Create the First Ever Ginger-Ale for Moms-To-Be 2Health News:Blue Cross and Blue Shield of Florida Awarded Prestigious J.D. Power and Associates Award for Second Year 2
... The Stryker Mainstay® ZIP Anchor is ... in several different sizes and suture options. ... 2.7mm, 3.5mm, and 4.5mm size with either ... #2, or #5 suture. Needles are attached ...
... The Stryker XCEL Suture Anchor is ... from Poly-L Lactic Acid (PLLA). The anchor ... rotates off the inserter until it "breaks" ... labrum repair, but it also frequently used ...
... an absorbable co-polymer synthesized from all-natural ... glycolic acid. Unlike the homopolymers in ... acid (PLLA) or 100% poly-glycolic acid ... (without crystallinity), meaning that its degradation ...
... Medicine™ POLYSORB™ Soft Tissue Anchor 3 mm is ... tissue to bone using sutures. The resorbable repair ... the bone, and is used to attach soft ... resorbable copolymer, derived from glycolide and lactide colored ...
Medicine Products: